Navigation Links
Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
Date:12/9/2009

SAN DIEGO, Dec. 9 /PRNewswire/ -- Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that the European Commission (EC) has granted orphan medicinal product designation for MP4CO for the treatment of sickle cell disease. This designation provides ten years of market exclusivity in the European Union (EU) following marketing authorization.

MP4CO is designed to deliver therapeutic levels of carbon monoxide (CO) to patients suffering from a sickle cell crisis. CO stabilizes hemoglobin S and prevents sickling of red blood cells. The addition of MP4CO to existing treatment protocols may alleviate pain associated with a sickle cell crisis and potentially reduce the duration of a crisis. Clinically this could mean preventing hospitalization, reducing the need for addictive narcotic analgesics, less time in the hospital if admitted, and an improved quality of life for patients with sickle cell disease.

The EC regulation for orphan medicinal products is designed to promote the development of drugs for rare diseases. Orphan medicinal product designation can confer numerous benefits to companies developing such treatments, including regulatory assistance, reduced regulatory fees associated with applying for marketing approval, and assistance with clinical trial design.

"Receiving orphan drug designation is an important step in our clinical development and planned commercialization of MP4CO," said Brian O'Callaghan, President and Chief Executive Officer of Sangart. "We are pleased to have reached this important milestone and look forward to working with the EMEA (European Agency for the Evaluation of Medicinal Products) to plan our clinical program and initiate our clinical studies. We remain committed to bringing a
'/>"/>

SOURCE Sangart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent
2. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
3. Sangart, Inc. Completes Series F Funding Round
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... SoundConnect’s 2015 ... introduce cutting edge communication technology, provide continued ... platform upgrades. This webinar series demonstrates online ... their quest to leverage web conferencing’s most ... SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our webinars ...
(Date:12/24/2014)... report expects global cell isolation and expansion market to ... carefully analyzed data about the vital drivers, restraints, trends, ... Copy of Report @ http://bit.ly/1yUxy0T , According ... will keep witnessing growth at an impressive CAGR during ... by rapid technological advancements, government funding and investments, and ...
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
Breaking Biology Technology:SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... Calif., May 12 An audit of the,state ... flaws,in Proposition 71 that created the agency, Consumer ... State Controller John Chiang found that with a,relatively ... complies with the requirements of Proposition 71, the,initiative ...
... May 12 Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ) ... at the Rodman & Renshaw 5th Annual Global,Healthcare Conference ... at Le,Meridien Beach Plaza Hotel in Monte Carlo, Monaco., ... presentation can be,accessed under "Calendar of Events" in the ...
... FREEPORT, N.Y., May 12 "What,s the difference ... repair my DNA?" Hundreds of,women are trying to ... will give me beautiful, healthy skin?, Bio-scientist ... care expertise -- more than 20 years of ...
Cached Biology Technology:Controller's Stem Cell Agency Audit Ignores California Agency's Built-in Flaws 2Controller's Stem Cell Agency Audit Ignores California Agency's Built-in Flaws 3A Scientist Dechipers the Code to Beautiful, Healthy Skin in 'The New Science of Perfect Skin' 2
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2
... turned off or left on in healthy ... common cancers and maybe help avoid them, Medical College ... alterations, called DNA methylation, in the body,s basic building ... and their cancerous counterpart to find telltale patterns that ...
... A new study finds that most older long-term cancer survivors ... health habits. The study also reveals that those survivors ... health and quality of life. Published in the September 1, ... the American Cancer Society, the research indicates that greater efforts ...
... The results of a national assessment of indoor location ... announced at Worcester Polytechnic Institute (WPI) during the 2009 ... Emergency Responders, which runs from Aug. 3 to 4. ... with funding from the Department of Homeland Security and ...
Cached Biology News:Cancer's distinctive pattern of gene expression could aid early screening and prevention 2Cancer's distinctive pattern of gene expression could aid early screening and prevention 3Cancer's distinctive pattern of gene expression could aid early screening and prevention 4Most older long-term cancer survivors have poor health habits 2Results of national assessment of first responder location systems to be announced Aug. 3 2Results of national assessment of first responder location systems to be announced Aug. 3 3Results of national assessment of first responder location systems to be announced Aug. 3 4
RABBIT ANTI WARFARIN...
For the quantitative determination of canine Interferon gamma,(IFN-γ) concentrations in cell culture supernates, serum and,plasma....
For the development of an immunoprecipitation assay to measure Chk1 kinase activity in cell lysates....
Bovine Serum Albumin Peroxidase Stabilizer Solution, 1 L...
Biology Products: